ATRC News and Press, AtriCure Inc. From 07/29/25

2025-07-29 19:14:40 ET More on AtriCure AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript AtriCure: Profits And Operating Leverage Are Needed Here Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial inf...

2025-07-29 16:05:08 ET More on AtriCure AtriCure: Profits And Operating Leverage Are Needed Here Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure Read the full article on Seekin...

Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17...

AstraZeneca PLC (AZN) is expected to report $1.09 for Q2 2025 Commvault Systems Inc. (CVLT) is expected to report $0.47 for Q1 2026 Ares Capital Corporation (ARCC) is expected to report $0.51 for Q2 2025 Northwest Bancshares Inc. (NWBI) is expected to report $0.29 for Q2 2025 Repl...

AtriCure Inc. (ATRC) is expected to report $-0.15 for Q2 2025

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 45 ...

2025-07-24 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis AtriCure, Inc. (Nasdaq: ATR...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2025 financial results on Tuesday, Ju...

2025-06-26 06:27:41 ET In November 2023, I believed that appeal was luring for AtriCure ( ATRC ) , with the business seeing solid revenue growth, yet more operating leverage was required. Following a meaningful pullback in the share price, I was gradually becoming more compelled...